It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery’s LogD7.4 validation confirms the assay’s accuracy and reproducibility across a wide range of compound lipophilicities. Using a classical shake‑flask approach with LC–MS/MS quantification, the method shows strong alignment with literature values and low variability across repeat assays, providing high‑quality lipophilicity data to support confident early‑stage ADME decision‑making.
About the Assay
Sygnature Discovery’s LogD7.4 assay quantifies compound lipophilicity using a classical shake‑flask partitioning approach between 1‑octanol and pH 7.4 phosphate buffer. Lipophilicity expressed as the Log of the distribution coefficient (LogD), is a key determinant of solubility, distribution, permeability and metabolic stability, making its accurate measurement essential for early‑stage drug discovery. The assay is designed to provide reliable LogD measurements across a broad chemical diversity, from hydrophilic to highly lipophilic compounds.
Protocol Summary
The LogD7.4 workflow involves partitioning of test compounds between 1-octanol and pH 7.4 buffer to quantify the relative distribution between polar and non‑polar environments. Test compound solutions utilizing 10 mM DMSO stocks are prepared in 1-octanol, equilibrated to ensure complete dissolution, and mixed with buffer in a defined phase ratio. Mechanical shaking ensures efficient mixing and enables the compound to distribute between the two phases.
Once equilibrium is reached, the two phases are separated by centrifugation, and aliquots are taken from each layer. Samples undergo appropriate dilution to fall within the analytical calibration range, and quantification is performed using LC–MS/MS. Measurements from multiple dilutions of buffer samples and nominal octanol standards are combined to generate a set of LogD ratios, from which accepted values are averaged to provide a final reported LogD7.4.
This structured workflow emphasizes reproducibility, minimizes handling variability and supports consistent data across compound classes. The standardised dilution and calibration strategy ensures robust quantification, enabling confident assessment of compounds spanning a wide range of lipophilicities.
Validation Results
Figure 1. Graph illustrating the mean measured LogD values for reference compounds vs literature data (1,2,3) in pH7.4 phosphate buffer:1-octanol
A subset of five compounds was further assessed in a dedicated intra‑assay evaluation (n = 6 incubations). The results demonstrated outstanding consistency, with coefficients of variation ranging from 0.9% to 8.7%, confirming reproducible performance within a single experimental run.
Summary
The assay delivers robust and reproducible partitioning across two immiscible phases following controlled equilibration, enabling accurate determination of concentration ratios. LC–MS/MS quantification ensures high sensitivity and broad dynamic range, supporting measurement of both polar and lipophilic molecules. The method supports high confidence in LogD7.4 characterization, facilitating medicinal chemistry optimization and enabling reliable structure‑property relationship interpretation.
Overall, the shake‑flask LogD7.4 assay provides high‑quality lipophilicity data aligned with industry standards and literature values, making it a powerful tool within early‑stage ADME screening workflows.
References
F. Lombardo, M.Y.Shaleva, K.A.Tupper, F.Gao, A tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds, J. Med. Chem. 44 (2001) 2490-2497
G. Morikawa, C. Suzuka, A. Shoji, Y. Shibusawa, A. Yanagida, High-throughput determination of octanol/water partition coefficients using a shake-flask method and novel two-phase solvent system. Journal of Pharmaceutical and Biomedical Analysis 117 (2019) 338-344
M. Wenlock, T. Potter, P. Barton, and R.P. Austin, A Method for Measuring the Lipophilicity of Compounds in Mixtures of 10. Society for Laboratory Automation and Screening (2011)